Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis
Alimentary Pharmacology & Therapeutics · 2026-02 · 63 (4) · 522-537
DOI: 10.1111/apt.70391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 29.10.2025. Verfasst von Kris V Kowdley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liver Institute Northwest, Elson S. Floyd College of Medicine, Washington State University, Seattle, USA. Hauptthemen laut MEDLINE: Alkaline Phosphatase, Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Chenodeoxycholic Acid. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background
Real‐world evidence on treatment persistence and its association with alkaline phosphatase (ALP) and clinical outcomes in primary biliary cholangitis (PBC) is limited.
Methods
We conducted a retrospective study using Komodo's US claims and laboratory data (09/2018–09/2023) of adults with PBC treated with ursodeoxycholic acid (UDCA), obeticholic acid (OCA), or concurrent UDCA/OCA. Persistence was defined as continuous treatment with ≤ 60‐day gaps. Cox models evaluated predictors of discontinuation, logistic models examined associations between discontinuation and normal ALP, and Cox models assessed normal ALP and clinical outcomes.
Results
Among 20,139 individuals starting UDCA ( n = 17,006), OCA ( n = 1,709), or concurrent UDCA/OCA ( n = 1,424), one‐year persistence was 50%, 51%, and 49%, respectively. Significant predictors of discontinuation included pruritus (hazard ratio [HR] = 1.09), fatigue (HR = 1.09), abdominal pain (HR = 1.08), African American race (HR = 1.36), Hispanic ethnicity (HR = 1.11), Medicaid coverage (HR = 1.13), baseline cirrhosis (HR = 1.08), portal hypertension (HR = 1.11), systemic lupus erythematosus (HR = 1.13) (all p < 0.01), and urinary infection (HR = 1.06, p = 0.017). Of 626 patients with baseline ALP levels ≥ 1.67 x upper limit of normal, 33%, 17%, and 11% in the UDCA, OCA, and concurrent UDCA/OCA cohorts, respectively, had normal ALP within 6–24 months ( p = 0.005 and p < 0.001 for OCA and concurrent vs. the UDCA cohort, respectively). UDCA discontinuation was associated with lower odds of having normal ALP. Normal ALP was associated with a reduced risk for mortality and clinical outcomes.
Conclusions
Treatment persistence is crucial in PBC as it is associated with normal ALP and significant improvement in clinical outcomes. Novel strategies and therapies are needed to enhance persistence and improve clinical benefits among individuals with PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Institute Northwest, Elson S. Floyd College of Medicine, Washington State University, Seattle, USA.
- Gilead Sciences, Foster City, California, USA.
- Stratevi, California, USA.
Förderung
- Gilead Sciences
Zitieren
APA
Kowdley, K. V., Ieyoub, J., Pan, Y., Samnaliev, M., Ito, D., & Perez, C. F. M. (2026). Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis. Alimentary Pharmacology & Therapeutics, 63(4), 522-537. https://doi.org/10.1111/apt.70391
Vancouver
Kowdley KV, Ieyoub J, Pan Y, Samnaliev M, Ito D, Perez CFM. Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis. Alimentary Pharmacology & Therapeutics. 2026;63(4):522-537. doi:10.1111/apt.70391
BibTeX
@article{Kowdley2026,
author = {Kowdley, Kris V and Ieyoub, Jonathan and Pan, Yi and Samnaliev, Mihail and Ito, Diane and Perez, C Fiorella Murillo},
title = {Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {4},
pages = {522--537},
doi = {10.1111/apt.70391}
}
EUVIMED